Lymphoma

P4, N=3800, Recruiting, Abramson Cancer Center at Penn Medicine | Phase classification: P=N/A --> P4

P=N/A, N=100, Not yet recruiting, Fondazione Italiana Linfomi - ETS

P2, N=144, Not yet recruiting, Sun Yat-sen University

P1, N=15, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> May 2026

P1, N=226, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting

P1/2, N=49, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Apr 2026 --> Nov 2025

TCR clonality was increased in EBV+ cHL, with trend towards further increase in clonality in HIV+. Through a multiomic approach of a well-characterized, HIV-inclusive cHL cohort from one of the most resource-limited countries in the world, we were able to recapitulate known, and identify novel molecular differences by HIV and EBV status.

However, clinicians should be aware of potential adverse effects, including infusion-related reactions, rashes, infections, as well as the increased risk of steroids-refractory acute graft-versus-host disease (GVHD), when mogamulizumab is used before allogeneic stem cell transplant (allo-SCT). Larger, prospective, randomized trials are needed to validate the current findings.

EA and PSE antioxidants increased hsa-miR-16-5p and hsa-miR-34a-5p expression, induced apoptosis, decreased cell proliferation, and stopped cancer cells in the G1 phase. Therefore, they can be considered promising compounds for helping the treatment of breast cancer.

In conclusion, Hi-C sequencing detects gene rearrangements crucial for diagnosis in an unbiased and molecular manner and showed high sensitivity and specificity in our study. These advantages of Hi-C sequencing offer help to improve the workflow of clinical pathology laboratories, diagnostic precision, and treatment of large B-cell lymphoma.

This multitargeted regimen addresses the biologic heterogeneity of MCL and permits flexible MRD-guided decisions on consolidation and maintenance. Trial Registration: ClinicalTrials.gov identifier: NCT04626791.